865 related articles for article (PubMed ID: 30705677)
21. Assessment of bone marrow lymphocytic status during tyrosine kinase inhibitor therapy and its relation to therapy response in chronic myeloid leukaemia.
El Missiry M; Adnan Awad S; Rajala HL; Al-Samadi A; Ekblom M; Markevän B; Åstrand-Grundström I; Wold M; Svedahl ER; Juhl BR; Bjerrum OW; Haulin I; Porkka K; Olsson-Strömberg U; Hjorth-Hansen H; Mustjoki S
J Cancer Res Clin Oncol; 2016 May; 142(5):1041-50. PubMed ID: 26746653
[TBL] [Abstract][Full Text] [Related]
22. The prognostic role of NKG2A expression for patients with chronic myeloid leukemia after treatment discontinuation.
Xu Z; Yin J; Sun Q; Hu J; Hong M; Qian S; Liu W
Leuk Lymphoma; 2022 Nov; 63(11):2616-2626. PubMed ID: 35758278
[TBL] [Abstract][Full Text] [Related]
23. Clinical Efficacy and Safety of First-Line Dasatinib Therapy and the Relevance of Velocity of BCR-ABL1 Transcript Decline for Achievement of Molecular Responses in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Report from the Juntendo Yamanashi Cooperative Study Group.
Takaku T; Iriyama N; Mitsumori T; Sato E; Gotoh A; Kirito K; Noguchi M; Koike M; Sakamoto J; Oba K; Komatsu N
Oncology; 2018; 94(2):85-91. PubMed ID: 29151104
[TBL] [Abstract][Full Text] [Related]
24. Direct effect of dasatinib on signal transduction pathways associated with a rapid mobilization of cytotoxic lymphocytes.
Iriyama N; Hatta Y; Takei M
Cancer Med; 2016 Nov; 5(11):3223-3234. PubMed ID: 27726309
[TBL] [Abstract][Full Text] [Related]
25. Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia.
Abbott BL
Clin Ther; 2012 Feb; 34(2):272-81. PubMed ID: 22285209
[TBL] [Abstract][Full Text] [Related]
26. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
27. ABL1-Directed Inhibitors for CML: Efficacy, Resistance and Future Perspectives.
Massimino M; Stella S; Tirrò E; Pennisi MS; Vitale SR; Puma A; Romano C; DI Gregorio S; Tomarchio C; DI Raimondo F; Manzella L
Anticancer Res; 2020 May; 40(5):2457-2465. PubMed ID: 32366389
[TBL] [Abstract][Full Text] [Related]
28. Early cytotoxic lymphocyte expansion contributes to a deep molecular response to dasatinib in patients with newly diagnosed chronic myeloid leukemia in the chronic phase: results of the D-first study.
Iriyama N; Fujisawa S; Yoshida C; Wakita H; Chiba S; Okamoto S; Kawakami K; Takezako N; Kumagai T; Inokuchi K; Ohyashiki K; Taguchi J; Yano S; Igarashi T; Kouzai Y; Morita S; Sakamoto J; Sakamaki H
Am J Hematol; 2015 Sep; 90(9):819-24. PubMed ID: 26103598
[TBL] [Abstract][Full Text] [Related]
29. Direct effect of dasatinib on proliferation and cytotoxicity of natural killer cells in in vitro study.
Uchiyama T; Sato N; Narita M; Yamahira A; Iwabuchi M; Furukawa T; Sone H; Takahashi M
Hematol Oncol; 2013 Sep; 31(3):156-63. PubMed ID: 23108877
[TBL] [Abstract][Full Text] [Related]
30. Tracking molecular relapse of chronic myeloid leukemia by measuring Hedgehog signaling status.
Cea M; Cagnetta A; Cirmena G; Garuti A; Rocco I; Palermo C; Pierri I; Reverberi D; Nencioni A; Ballestrero A; Gobbi M; Carella AM; Patrone F
Leuk Lymphoma; 2013 Feb; 54(2):342-52. PubMed ID: 22762548
[TBL] [Abstract][Full Text] [Related]
31. Final 3-year Results of the Dasatinib Discontinuation Trial in Patients With Chronic Myeloid Leukemia Who Received Dasatinib as a Second-line Treatment.
Okada M; Imagawa J; Tanaka H; Nakamae H; Hino M; Murai K; Ishida Y; Kumagai T; Sato S; Ohashi K; Sakamaki H; Wakita H; Uoshima N; Nakagawa Y; Minami Y; Ogasawara M; Takeoka T; Akasaka H; Utsumi T; Uike N; Sato T; Ando S; Usuki K; Mizuta S; Hashino S; Nomura T; Shikami M; Fukutani H; Ohe Y; Kosugi H; Shibayama H; Maeda Y; Fukushima T; Yamazaki H; Tsubaki K; Kukita T; Adachi Y; Nataduka T; Sakoda H; Yokoyama H; Okamoto T; Shirasugi Y; Onishi Y; Nohgawa M; Yoshihara S; Morita S; Sakamoto J; Kimura S;
Clin Lymphoma Myeloma Leuk; 2018 May; 18(5):353-360.e1. PubMed ID: 29610029
[TBL] [Abstract][Full Text] [Related]
32. Important therapeutic targets in chronic myelogenous leukemia.
Kantarjian HM; Giles F; Quintás-Cardama A; Cortes J
Clin Cancer Res; 2007 Feb; 13(4):1089-97. PubMed ID: 17317816
[TBL] [Abstract][Full Text] [Related]
33. Effects of first- and second-generation tyrosine kinase inhibitor therapy on glucose and lipid metabolism in chronic myeloid leukemia patients: a real clinical problem?
Iurlo A; Orsi E; Cattaneo D; Resi V; Bucelli C; Orofino N; Sciumè M; Elena C; Grancini V; Consonni D; Orlandi EM; Cortelezzi A
Oncotarget; 2015 Oct; 6(32):33944-51. PubMed ID: 26376678
[TBL] [Abstract][Full Text] [Related]
34. In vitro anti-leukaemia activity of pyrrolo[1,2-b][1,2,5]benzothiadiazepines (PBTDs).
Marfe G; Di Stefano C
Recent Pat Anticancer Drug Discov; 2010 Jan; 5(1):58-68. PubMed ID: 19663771
[TBL] [Abstract][Full Text] [Related]
35. Effects of BCR-ABL inhibitors on anti-tumor immunity.
Krusch M; Salih HR
Curr Med Chem; 2011; 18(34):5174-84. PubMed ID: 22087818
[TBL] [Abstract][Full Text] [Related]
36. Killer immunoglobulin-like receptor genotypes and chronic myeloid leukemia outcomes after imatinib cessation for treatment-free remission.
Dumas PY; Bérard E; Bréal C; Dulucq S; Réa D; Nicolini F; Forcade E; Dufossée M; Pasquet JM; Turcq B; Bidet A; Milpied N; Déchanet-Merville J; Lafarge X; Etienne G; Mahon FX;
Cancer Med; 2019 Sep; 8(11):4976-4985. PubMed ID: 31287239
[TBL] [Abstract][Full Text] [Related]
37. Real-World Effectiveness of Dasatinib Versus Imatinib in Newly Diagnosed Patients With Chronic Myeloid Leukemia.
Klink AJ; Keating SJ; Brokars J; Feinberg B; Jabbour E
Clin Lymphoma Myeloma Leuk; 2024 Mar; 24(3):149-157. PubMed ID: 38135632
[TBL] [Abstract][Full Text] [Related]
38. Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy.
Kreutzman A; Juvonen V; Kairisto V; Ekblom M; Stenke L; Seggewiss R; Porkka K; Mustjoki S
Blood; 2010 Aug; 116(5):772-82. PubMed ID: 20413659
[TBL] [Abstract][Full Text] [Related]
39. NKT-Like (CD3+CD56+) Cells in Chronic Myeloid Leukemia Patients Treated With Tyrosine Kinase Inhibitors.
Almeida JS; Couceiro P; López-Sejas N; Alves V; Růžičková L; Tarazona R; Solana R; Freitas-Tavares P; Santos-Rosa M; Rodrigues-Santos P
Front Immunol; 2019; 10():2493. PubMed ID: 31695700
[TBL] [Abstract][Full Text] [Related]
40. Cost Effectiveness of Imatinib, Dasatinib, and Nilotinib as First-Line Treatment for Chronic-Phase Chronic Myeloid Leukemia in China.
Li N; Zheng B; Cai HF; Yang J; Luo XF; Weng LZ; Zhan FM; Liu MB
Clin Drug Investig; 2018 Jan; 38(1):79-86. PubMed ID: 29027641
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]